<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2638">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347239</url>
  </required_header>
  <id_info>
    <org_study_id>CD12_COVID-19</org_study_id>
    <nct_id>NCT04347239</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoDyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoDyn, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140)&#xD;
      administered as weekly subcutaneous injection in subjects with severe or critical COVID-19&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design&#xD;
      multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients&#xD;
      with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection.&#xD;
      Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or&#xD;
      placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.&#xD;
&#xD;
      The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Day 0 refers to the data of randomization/first treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Day 0 refers to the data of randomization/first treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)</measure>
    <time_frame>Day 14</time_frame>
    <description>A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)</measure>
    <time_frame>Day 28</time_frame>
    <description>A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.</measure>
    <time_frame>Day 14</time_frame>
    <description>The SOFA score assessment will be based on PaO2/FiO2, platelets, Glasgow coma scale (GCS), bilirubin, Mean arterial pressure OR administration of vasoactive agents required, and Serum creatinine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>700mg Leronlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leronlimab (700mg)</intervention_name>
    <description>Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)</description>
    <arm_group_label>700mg Leronlimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female adult ≥ 18 years of age at time of screening.&#xD;
&#xD;
          2. Subjects hospitalized with severe or critical illness caused by coronavirus 2019&#xD;
             infection as defined below:&#xD;
&#xD;
             A. Severe Illness:&#xD;
&#xD;
             - Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days&#xD;
             of screening&#xD;
&#xD;
             AND&#xD;
&#xD;
             Symptoms of severe systemic illness/infection with COVID-19:&#xD;
&#xD;
             - At least 1 of the following: fever, cough, sore throat, malaise, headache, muscle&#xD;
             pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe&#xD;
             lower respiratory symptoms including dyspnea at rest or respiratory distress&#xD;
&#xD;
             AND&#xD;
&#xD;
             Clinical signs indicative of severe systemic illness/infection with COVID-19, with at&#xD;
             least 1 of the following:&#xD;
&#xD;
             - RR ≥ 30, HR ≥ 125, SaO2 &lt;93% on room air or requires &gt; 2L oxygen by NC in order&#xD;
             maintain SaO2 ≥93%, PaO2/FiO2 &lt;300&#xD;
&#xD;
             AND&#xD;
&#xD;
             - None of the following: Respiratory failure (defined by endotracheal intubation and&#xD;
             mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive&#xD;
             positive pressure ventilation, or clinical diagnosis of respiratory failure in setting&#xD;
             of resource limitations), Septic shock (defined by SBP &lt; 90 mm Hg, or Diastolic BP &lt;&#xD;
             60 mm Hg), Multiple organ dysfunction/failure&#xD;
&#xD;
             B. Critical Illness:&#xD;
&#xD;
             - Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days&#xD;
             of screening&#xD;
&#xD;
             AND&#xD;
&#xD;
             Evidence of critical illness, defined by at least 1 of the following:&#xD;
&#xD;
             - Respiratory failure defined based on resource utilization requiring at least 1 of&#xD;
             the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by&#xD;
             high-flow nasal cannula, noninvasive positive pressure ventilation, ECMO, or clinical&#xD;
             diagnosis of respiratory failure (in setting of resource limitation)&#xD;
&#xD;
             OR&#xD;
&#xD;
             - Shock (defined by SBP &lt; 90 mm Hg, or Diastolic BP &lt; 60 mm Hg or requiring&#xD;
             vasopressors)&#xD;
&#xD;
             OR&#xD;
&#xD;
             -Multiple organ dysfunction/failure&#xD;
&#xD;
          3. Subject, if intubated, positive endexpiratory pressure (PEEP) &lt;15 cmH2O with PaO2/FiO2&#xD;
             &gt;150 mmHg.&#xD;
&#xD;
          4. Electrocardiogram (ECG) with no clinically significant findings as assessed by the&#xD;
             Investigator&#xD;
&#xD;
          5. Subject (or legally authorized representative) provides written informed consent prior&#xD;
             to initiation of any study procedures.&#xD;
&#xD;
          6. Understands and agrees to comply with planned study procedures.&#xD;
&#xD;
          7. Women of childbearing potential and their partner must agree to use at least one&#xD;
             highly effective method of contraception (e.g., hormonal contraceptives [implants,&#xD;
             injectables, combination oral contraceptives, transdermal patches, or contraceptive&#xD;
             rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with do-not-resuscitate (DNR) and/or do-not-intubate (DNI) orders or expected&#xD;
             to be made DNR/DNI in setting of resource limitations or family wishes.&#xD;
&#xD;
          2. Not a candidate for dialysis or continuation of care (or full medical support) in&#xD;
             setting of resource limitations.&#xD;
&#xD;
          3. Subject on continuous vasopressors (at the dose of norepinephrine &gt;20μg/min and/or&#xD;
             vasopressin &gt;0.04 units/kg/min) for &gt;48 hours at time of screening.&#xD;
&#xD;
          4. Subjects who have a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to leronlimab (PRO 140) are not eligible.&#xD;
&#xD;
          5. Inability to provide informed consent or to comply with test requirements&#xD;
&#xD;
          6. Consideration by the investigator, for safety reasons, that the subject is an&#xD;
             unsuitable candidate to receive study treatment&#xD;
&#xD;
          7. Pregnancy or breast feeding&#xD;
&#xD;
          8. Subject participating in another study with for an investigational treatment for&#xD;
             COVID-19.&#xD;
&#xD;
        Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without&#xD;
        azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory&#xD;
        treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and&#xD;
        anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included&#xD;
        and may continue to receive these agents as part of standard-of-care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kush Dhody, MBBS, MS, CCRA</last_name>
    <phone>301-956-2536</phone>
    <email>kushd@amarexcro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Cardiovascular, LLC</name>
      <address>
        <city>Alexander City</city>
        <state>Alabama</state>
        <zip>35010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Forbus, RN, BSN</last_name>
      <phone>256-215-5323</phone>
    </contact>
    <investigator>
      <last_name>William Ross Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Sanchez</last_name>
      <phone>714-446-5620</phone>
      <email>Blanca.Sanchez@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>David J Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lopez</last_name>
      <phone>310-794-8043</phone>
      <email>NancyRLopez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Otto Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veterans' Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Zoble</last_name>
      <phone>813-631-3671</phone>
      <email>Adam.Zoble@va.gov</email>
    </contact>
    <investigator>
      <last_name>Koushik Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Research &amp; Education (CARE)</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Davis</last_name>
      <phone>617-735-4466</phone>
      <email>Cdavis6@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sabrina Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Barnabas</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Subroto Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Whitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Kiledjian</last_name>
      <phone>201-541-6312</phone>
      <email>pkiledjian@holyname.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin De La Rosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Wilson</last_name>
      <phone>718-920-7916</phone>
    </contact>
    <investigator>
      <last_name>Harish Seethamraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Community Hospital of Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Bilik</last_name>
      <phone>718-692-5336</phone>
      <email>mbilik@nych.com</email>
    </contact>
    <investigator>
      <last_name>Isaia Avraham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen O'Brien</last_name>
      <email>kathleen.obrien@novanthealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Pailing Richards</last_name>
      <phone>704-996-7627</phone>
      <email>pcrichards@novanthealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kiran Devulapally, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital Corvallis</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Mock</last_name>
      <phone>541-768-4352</phone>
      <email>stmock@samhealth.org</email>
    </contact>
    <investigator>
      <last_name>Brian Delmonaco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marcel Curlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Wang</last_name>
      <email>Samantha.wang@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Uriel Sandkovsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinali Zaveri, MD</last_name>
      <phone>713-873-2353</phone>
      <email>hzaveri@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Kalpalatha Guntupalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Lake</last_name>
      <phone>713-500-6767</phone>
      <email>Jordan.e.lake@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jordan Lake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

